Expert insights. Personalized for you.
A novel way to control biologic signaling allows cellular function to be modulated via cell phone, according to research presented at the American Chemical Society’s annual meeting Tuesday by researchers at the University of Maryland MORE
These results will help researchers to identify at an early stage the people most at risk of developing the disease, well before the first cognitive symptoms appear Credit: ©ULiège/CRC In Vivo Imaging Study conducted by researchers from the GIGA CRC In vivo Imaging laboratory at ULiège demonstrates, for the first time in humans, how the […]. MORE
Nimbus Therapeutics Presents In Vivo Data Showing Single-Agent and Combination Activity of HPK1 Inhibitor Nimbus Therapeutics Presents In Vivo Data Showing Single-Agent and Combination Activity of HPK1 Inhibitor CAMBRIDGE, Mass.–(BUSINESS MORE
Editas Medicine to Present Preclinical Data Demonstrating Advancements in In Vivo Gene Editing Approach for the Treatment of Genetic Ocular Diseases at the Association for Research in Vision and Ophthalmology Annual Meeting Editas Medicine to Present Preclinical Data Demonstrating Advancements … Continue reading → GlobeNewswire MORE
5, 2020) — Genetic modifier HDAC6 was found to control tumor growth and halt metastasis in triple-negative breast cancer in vivo, according to a new study published […]. GW Cancer Center researchers demonstrate for the first time that HDAC6 inhibitors drugs can both improve response to immunotherapy and diminish the invasiveness of breast cancer WASHINGTON (Aug. MORE
This model has the benefit of giving companies direct oversight of their in vivo studies, allowing them to move faster while operationalizing every dollar of their seed financing MORE
Diurnal in vivo xylem sap glucose and sucrose monitoring using implantable organic electrochemical transistor sensors Credit: Thor Balkhed Researchers at Linköping University, Sweden, have developed biosensors that make it possible to monitor sugar levels in real time deep in the plant tissues – something that has previously been impossible. MORE
Oncotarget recently published a novel format for recombinant antibody-interleukin-2 fusion proteins exhibits superior tumor-targeting properties in vivo which reported that here, the authors describe four novel formats for the L19-IL2 fusion Credit: Correspondence to – Dario Neri – dario.neri@pharma.ethz.ch MORE
Positive preclinical in vivo results with AFFiRiS’ antibody mAB C6-17 to treat Huntington’s disease to be presented at the 16th Annual Huntington’s Disease Therapeutics Conference Positive preclinical in vivo results with AFFiRiS’ antibody mAB C6-17 to treat Huntington’s disease to … Continue reading → GlobeNewswire MORE
Theratechnologies Presents New In Vivo Pre-Clinical Data at AACR Demonstrating Significant Anti-Tumor Activity of TH1902 in All Studied Cancer Types Theratechnologies Presents New In Vivo Pre-Clinical Data at AACR Demonstrating Significant Anti-Tumor Activity of TH1902 in All Studied Cancer Types … Continue reading → GlobeNewswire MORE
Kymera Therapeutics Presents Late-Breaking Preclinical Data on IRAK4 Degrader KT-474 at IMMUNOLOGY2021™ Annual Meeting Kymera Therapeutics Presents Late-Breaking Preclinical Data on IRAK4 Degrader KT-474 at IMMUNOLOGY2021™ Annual Meeting New in vivo data demonstrate the broad anti-inflammatory activity of KT-474 and … Continue reading → GlobeNewswire MORE
Antibodies in blood of vaccinated individuals neutralised in vivo version of variant MORE
CorWave Presents an Unprecedented Chronic In Vivo Study at the 41st Annual Meeting of the International Society of Heart and Lung Transplantation CorWave Presents an Unprecedented Chronic In Vivo Study at the 41st Annual Meeting of the International Society of … Continue reading → Business Wire MORE
Credit: CNIO It has recently been described that infection by some enteroviruses – a genus of viruses that commonly cause diseases of varying severity – could potentially trigger diabetes, although its direct effect ‘in vivo’ as well as its mechanism of action at the molecular level were unknown. MORE
Researchers in China have taken the first step towards a new way of treating gastric wounds by using a microrobot combined with the new concept of “in situ in vivo bioprinting” to carry out tissue repair inside the body. Their study, published today in the IOP Publishing journal Biofabrication, establishes proof-of-concept for this new method […]. MORE
London, November 4th, 2020: NanoMab Technology Limited, a privately held biopharmaceutical company focussing on cancer precision therapies, today announced that it had received CTA Acceptance from the Medicines Healthcare products Regulatory Agency (MHRA) to carry out a Phase II clinical Study for its NM-01 product MORE
Draper, in one of the latest lab-on-a-chip advances, has shown that its dynamic, in vitro tumor microenvironment can be used to distinguish tumor responses against two different checkpoint inhibitors in three mouse lines MORE
Sanofi today acquired Tidal Therapeutics, a privately owned, pre-clinical stage biotech company with a novel mRNA-based approach for in vivo reprogramming of immune cells. Tidal Therapeutics utilizes a novel mRNA-based approach to in vivo reprogramming of immune cells. MORE
New Preclinical Data Presented at the 2021 American Society of Genetic & Cell Therapy Annual Meeting Highlights Precision BioSciences’ ARCUS In Vivo Genome Editing New Preclinical Data Presented at the 2021 American Society of Genetic & Cell Therapy Annual Meeting … Continue reading → Business Wire MORE
an important non-canonical DNA secondary structure in vivo and in vitro, G-quadruplexes (GQs) have been widely investigated in many fields including biology, … Continue reading → #newsBiotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Scientists discover dynamic trimolecular G-quadruplex.As MORE
Using innovative in vivo imaging approaches, scientists […]. Monoclonal antibodies are part of the therapeutic arsenal for eliminating cancer cells. Some make use of the immune system to act and belong to a class of treatment called “immunotherapies.” ” But how do these antibodies function within the tumor? And how can we hope to improve their efficacy? MORE
Intellia Therapeutics presented preclinical data of its non-viral genome editing platform at the Keystone eSymposium: Precision Engineering of the Genome, Epigenome and Transcriptome MORE
Sanofi has acquired Cambridge, Massachusetts biotech Tidal Therapeutics: gaining its novel mRNA-based approach for in vivo reprogramming of immune cells. MORE
SAN DIEGO and BOSTON, Sept. 02, 2020 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. Nasdaq: SRNE, “Sorrento”) and SmartPharm Therapeutics, Inc. (“SmartPharm”) announced today that Sorrento has completed the acquisition of SmartPharm, a gene-encoded protein therapeutics company developing non-viral DNA and … Continue reading → GlobeNewswire MORE
New in vivo data for colon cancer show anti-tumor immunity in 100% of mice In vivo breast cancer data show a significant delay in challenge tumor uptake GARDEN CITY, N.Y., 19, 2020 (GLOBE NEWSWIRE) — Beyond Air, Inc. NASDAQ: … Continue reading → GlobeNewswire MORE
Singapore scientists uncover potential role of long non-coding RNAs in pancreatic cancer Credit: From Figure 4 in Liu, S., Wnt-regulated lncRNA discovery enhanced by in vivo identification and CRISPRi functional validation. MORE
Built by CRISPR leaders including Jennifer Doudna to enable best-in-class in vivo therapeutics that permanently treat the underlying cause of disease Initial $20 million Series A led by Andreessen Horowitz Collaboration with Biogen Inc. MORE
Maculus plans to raise USD3 million on a USD8 million valuation for a 12-18 month period, including initial in-vivo animal studies and completion of in-vitro / in-vivo drug elution studies. MORE
Gong Chen at Jinan University, Guangzhou, China recently reported the first non-human primate study demonstrating successful in vivo neural regeneration from brain internal glial cells for stroke repair. MORE
Credit: Lei Dong, Nanjing University Scientists from Nanjing University and the University of Macau have devised a new approach to extend the survival of transplanted probiotics in vivo, enhancing the efficacy of cancer chemo-/immunotherapies in mice. MORE
The biotech won a grant from the foundation two days after dosing the first patient in a study of an in vivo CRISPR medicine, a milestone for the company and the technology MORE
Qurient Enrolls First Patient in Q702 U.S. Phase 1 Study Qurient Enrolls First Patient in Q702 U.S. MORE
–(BUSINESS WIRE)–#bartonella–A groundbreaking in vivo clinical study conducted by Dr. Richard Horowitz, serving on the U.S. NEW HAVEN, Conn.–(BUSINESS Department of Health and Human Services Babesia and Tick-borne Pathogens subcommittee, has found that an eight-week course of the proven leprosy drug … Continue reading → Business Wire MORE
Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Sanofi pays $160M for mRNA tech to reprogram T cells in vivo.Sanofi pays $160M for mRNA tech to reprogram T cells in vivo ntaylor Mon, 04/12/2021 – … Continue reading → #news MORE
In vivo efficacy on a par with gold standard deruxtecan-based ADCs Poster to be presented at World ADC meeting on 17 September 2020 AMSTERDAM–(BUSINESS WIRE)–Synaffix B.V., MORE
“Our work establishes that it is now possible to uniquely distinguish tens of thousands of cells over several months of growth in vivo, reconstruct deeply resolved and accurate cell phylogenies and […]. A new method for tracing real-time cancer progression across thousands of cells reveals novel insights into the rates, routes and drivers of cancer metastasis. MORE
Recce Announces Positive Intranasal Animal Data against SARS-CoV-2 in International Study Recce Announces Positive Intranasal Animal Data against SARS-CoV-2 in International Study Highlights: RECCE® 327 and RECCE® 529 demonstrated dose-dependent activity in-vivo against SARS-CoV-2 virus in Syrian golden hamsters, a … Continue reading → GlobeNewswire MORE
NKarta Therapeutics is using engineered chimeric antigen receptor natural killer T cells (CAR-NKT cells) for allogeneic therapy, showing substantial benefits both in vitro and in vivo, according to James Trager, CSO, speaking Wednesday at the virtual CAR-TCR Summit – Europe MORE
First patient was administered today The trial aims at validating the safety of continuous administration of Ivermectin in oral form Simultaneously, several long-acting injectable formulations based on MedinCell’s BEPO® technology are being tested in vivo A 1-month active injectable prophylactic … Continue reading → Business Wire MORE
In-Vivo Related Topics BioTech 365
APRIL 8, 2021
Nimbus Therapeutics Presents In Vivo Data Showing Single-Agent and Combination Activity of HPK1 Inhibitor Nimbus Therapeutics Presents In Vivo Data Showing Single-Agent and Combination Activity of HPK1 Inhibitor CAMBRIDGE, Mass.–(BUSINESS
BioTech 365
NOVEMBER 9, 2020
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
BioTech 365
APRIL 28, 2021
CorWave Presents an Unprecedented Chronic In Vivo Study at the 41st Annual Meeting of the International Society of Heart and Lung Transplantation CorWave Presents an Unprecedented Chronic In Vivo Study at the 41st Annual Meeting of the International Society of … Continue reading → Business Wire
BioTech 365
APRIL 12, 2021
Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Sanofi pays $160M for mRNA tech to reprogram T cells in vivo.Sanofi pays $160M for mRNA tech to reprogram T cells in vivo ntaylor Mon, 04/12/2021 – … Continue reading → #news
Scienmag
SEPTEMBER 28, 2020
BioTech 365
APRIL 27, 2021
Positive preclinical in vivo results with AFFiRiS’ antibody mAB C6-17 to treat Huntington’s disease to be presented at the 16th Annual Huntington’s Disease Therapeutics Conference Positive preclinical in vivo results with AFFiRiS’ antibody mAB C6-17 to treat Huntington’s disease to … Continue reading → GlobeNewswire
BioTech 365
MAY 11, 2021
New Preclinical Data Presented at the 2021 American Society of Genetic & Cell Therapy Annual Meeting Highlights Precision BioSciences’ ARCUS In Vivo Genome Editing New Preclinical Data Presented at the 2021 American Society of Genetic & Cell Therapy Annual Meeting … Continue reading → Business Wire
BioTech 365
APRIL 10, 2021
Theratechnologies Presents New In Vivo Pre-Clinical Data at AACR Demonstrating Significant Anti-Tumor Activity of TH1902 in All Studied Cancer Types Theratechnologies Presents New In Vivo Pre-Clinical Data at AACR Demonstrating Significant Anti-Tumor Activity of TH1902 in All Studied Cancer Types … Continue reading → GlobeNewswire
BioSpace
MARCH 10, 2021
Intellia Therapeutics presented preclinical data of its non-viral genome editing platform at the Keystone eSymposium: Precision Engineering of the Genome, Epigenome and Transcriptome
BioSpace
SEPTEMBER 29, 2020
Draper, in one of the latest lab-on-a-chip advances, has shown that its dynamic, in vitro tumor microenvironment can be used to distinguish tumor responses against two different checkpoint inhibitors in three mouse lines
Scienmag
AUGUST 12, 2020
Researchers in China have taken the first step towards a new way of treating gastric wounds by using a microrobot combined with the new concept of “in situ in vivo bioprinting” to carry out tissue repair inside the body. Their study, published today in the IOP Publishing journal Biofabrication, establishes proof-of-concept for this new method […].
BioTech 365
MAY 1, 2021
Editas Medicine to Present Preclinical Data Demonstrating Advancements in In Vivo Gene Editing Approach for the Treatment of Genetic Ocular Diseases at the Association for Research in Vision and Ophthalmology Annual Meeting Editas Medicine to Present Preclinical Data Demonstrating Advancements … Continue reading → GlobeNewswire
BioTech 365
OCTOBER 19, 2020
New in vivo data for colon cancer show anti-tumor immunity in 100% of mice In vivo breast cancer data show a significant delay in challenge tumor uptake GARDEN CITY, N.Y., 19, 2020 (GLOBE NEWSWIRE) — Beyond Air, Inc. NASDAQ: … Continue reading → GlobeNewswire
BioSpace
AUGUST 19, 2020
A novel way to control biologic signaling allows cellular function to be modulated via cell phone, according to research presented at the American Chemical Society’s annual meeting Tuesday by researchers at the University of Maryland
Bio Pharma Dive
NOVEMBER 11, 2020
The biotech won a grant from the foundation two days after dosing the first patient in a study of an in vivo CRISPR medicine, a milestone for the company and the technology
Pharma Times
JANUARY 21, 2021
Antibodies in blood of vaccinated individuals neutralised in vivo version of variant
Drug Discovery Today
NOVEMBER 5, 2020
London, November 4th, 2020: NanoMab Technology Limited, a privately held biopharmaceutical company focussing on cancer precision therapies, today announced that it had received CTA Acceptance from the Medicines Healthcare products Regulatory Agency (MHRA) to carry out a Phase II clinical Study for its NM-01 product
BioTech 365
SEPTEMBER 2, 2020
SAN DIEGO and BOSTON, Sept. 02, 2020 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. Nasdaq: SRNE, “Sorrento”) and SmartPharm Therapeutics, Inc. (“SmartPharm”) announced today that Sorrento has completed the acquisition of SmartPharm, a gene-encoded protein therapeutics company developing non-viral DNA and … Continue reading → GlobeNewswire
BioSpace
NOVEMBER 10, 2020
This model has the benefit of giving companies direct oversight of their in vivo studies, allowing them to move faster while operationalizing every dollar of their seed financing
Scienmag
JANUARY 25, 2021
These results will help researchers to identify at an early stage the people most at risk of developing the disease, well before the first cognitive symptoms appear Credit: ©ULiège/CRC In Vivo Imaging Study conducted by researchers from the GIGA CRC In vivo Imaging laboratory at ULiège demonstrates, for the first time in humans, how the […].
BioPharma Reporter
APRIL 12, 2021
Sanofi has acquired Cambridge, Massachusetts biotech Tidal Therapeutics: gaining its novel mRNA-based approach for in vivo reprogramming of immune cells.
BioSpace
FEBRUARY 17, 2021
NKarta Therapeutics is using engineered chimeric antigen receptor natural killer T cells (CAR-NKT cells) for allogeneic therapy, showing substantial benefits both in vitro and in vivo, according to James Trager, CSO, speaking Wednesday at the virtual CAR-TCR Summit – Europe
BioTech 365
MAY 10, 2021
Kymera Therapeutics Presents Late-Breaking Preclinical Data on IRAK4 Degrader KT-474 at IMMUNOLOGY2021™ Annual Meeting Kymera Therapeutics Presents Late-Breaking Preclinical Data on IRAK4 Degrader KT-474 at IMMUNOLOGY2021™ Annual Meeting New in vivo data demonstrate the broad anti-inflammatory activity of KT-474 and … Continue reading → GlobeNewswire
BioTech 365
JANUARY 26, 2021
Qurient Enrolls First Patient in Q702 U.S. Phase 1 Study Qurient Enrolls First Patient in Q702 U.S.
Pharma Mirror
FEBRUARY 18, 2021
Maculus plans to raise USD3 million on a USD8 million valuation for a 12-18 month period, including initial in-vivo animal studies and completion of in-vitro / in-vivo drug elution studies.
Scienmag
FEBRUARY 10, 2021
Diurnal in vivo xylem sap glucose and sucrose monitoring using implantable organic electrochemical transistor sensors Credit: Thor Balkhed Researchers at Linköping University, Sweden, have developed biosensors that make it possible to monitor sugar levels in real time deep in the plant tissues – something that has previously been impossible.
Scienmag
FEBRUARY 10, 2021
Credit: Lei Dong, Nanjing University Scientists from Nanjing University and the University of Macau have devised a new approach to extend the survival of transplanted probiotics in vivo, enhancing the efficacy of cancer chemo-/immunotherapies in mice.
BioTech 365
MARCH 9, 2021
an important non-canonical DNA secondary structure in vivo and in vitro, G-quadruplexes (GQs) have been widely investigated in many fields including biology, … Continue reading → #newsBiotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Scientists discover dynamic trimolecular G-quadruplex.As
BioTech 365
OCTOBER 6, 2020
Built by CRISPR leaders including Jennifer Doudna to enable best-in-class in vivo therapeutics that permanently treat the underlying cause of disease Initial $20 million Series A led by Andreessen Horowitz Collaboration with Biogen Inc.
Scienmag
FEBRUARY 17, 2021
In particularly, the use of RE luminescent materials for in vitro and in vivo imaging can easily […].
BioTech 365
AUGUST 31, 2020
Scienmag
OCTOBER 20, 2020
Credit: CNIO It has recently been described that infection by some enteroviruses – a genus of viruses that commonly cause diseases of varying severity – could potentially trigger diabetes, although its direct effect ‘in vivo’ as well as its mechanism of action at the molecular level were unknown.
Scienmag
JANUARY 21, 2021
“Our work establishes that it is now possible to uniquely distinguish tens of thousands of cells over several months of growth in vivo, reconstruct deeply resolved and accurate cell phylogenies and […]. A new method for tracing real-time cancer progression across thousands of cells reveals novel insights into the rates, routes and drivers of cancer metastasis.
Scienmag
NOVEMBER 16, 2020
Singapore scientists uncover potential role of long non-coding RNAs in pancreatic cancer Credit: From Figure 4 in Liu, S., Wnt-regulated lncRNA discovery enhanced by in vivo identification and CRISPRi functional validation.
Scienmag
NOVEMBER 12, 2020
Gong Chen at Jinan University, Guangzhou, China recently reported the first non-human primate study demonstrating successful in vivo neural regeneration from brain internal glial cells for stroke repair.
Scienmag
FEBRUARY 22, 2021
Using innovative in vivo imaging approaches, scientists […]. Monoclonal antibodies are part of the therapeutic arsenal for eliminating cancer cells. Some make use of the immune system to act and belong to a class of treatment called “immunotherapies.” ” But how do these antibodies function within the tumor? And how can we hope to improve their efficacy?
BioTech 365
DECEMBER 23, 2020
Recce Announces Positive Intranasal Animal Data against SARS-CoV-2 in International Study Recce Announces Positive Intranasal Animal Data against SARS-CoV-2 in International Study Highlights: RECCE® 327 and RECCE® 529 demonstrated dose-dependent activity in-vivo against SARS-CoV-2 virus in Syrian golden hamsters, a … Continue reading → GlobeNewswire
Scienmag
OCTOBER 23, 2020
Oncotarget recently published a novel format for recombinant antibody-interleukin-2 fusion proteins exhibits superior tumor-targeting properties in vivo which reported that here, the authors describe four novel formats for the L19-IL2 fusion Credit: Correspondence to – Dario Neri – dario.neri@pharma.ethz.ch
BioTech 365
OCTOBER 28, 2020
–(BUSINESS WIRE)–#bartonella–A groundbreaking in vivo clinical study conducted by Dr. Richard Horowitz, serving on the U.S. NEW HAVEN, Conn.–(BUSINESS Department of Health and Human Services Babesia and Tick-borne Pathogens subcommittee, has found that an eight-week course of the proven leprosy drug … Continue reading → Business Wire
BioTech 365
SEPTEMBER 29, 2020
First patient was administered today The trial aims at validating the safety of continuous administration of Ivermectin in oral form Simultaneously, several long-acting injectable formulations based on MedinCell’s BEPO® technology are being tested in vivo A 1-month active injectable prophylactic … Continue reading → Business Wire
Scienmag
AUGUST 5, 2020
5, 2020) — Genetic modifier HDAC6 was found to control tumor growth and halt metastasis in triple-negative breast cancer in vivo, according to a new study published […]. GW Cancer Center researchers demonstrate for the first time that HDAC6 inhibitors drugs can both improve response to immunotherapy and diminish the invasiveness of breast cancer WASHINGTON (Aug.
The Pharma Data
APRIL 9, 2021
Sanofi today acquired Tidal Therapeutics, a privately owned, pre-clinical stage biotech company with a novel mRNA-based approach for in vivo reprogramming of immune cells. Tidal Therapeutics utilizes a novel mRNA-based approach to in vivo reprogramming of immune cells.
54 
Let's personalize your content